Skip to main content

Table 3 Results of incremental cost-effectiveness ratios (ICER) in base case and probability sensitivity analysis

From: Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?

Short-term (at end of 12-months)

NRT + counselling

NRT + counselling

+ genetic test

Difference

 

Cost for 1000 persons in each arm

$802,100

$1,158,000

$355,600

 

Number of quitters @ 12 months

60

110

50

 

ICER - per quitter @ 12 months

-

-

$7,112

 

Long-term (at end of 35 years)

    

Mean cost per person

$6,600

$6,900

$300

 

QALYs gained per person

14.288

14.298

0.0109

 

ICER - QALYs gained per person

-

-

$27,5721

 

Monte Carlo simulated ICERs

Incremental costs2

Incremental

QALYs

ICERs (QALYs)

(95% CIs)

Base case ICER

$299.46

0.0109

$34,6873

($12,483, $87,734)

Initial cohort aged 30 years

$341.69

0.0032

$133,409

($53,502, $361,376)

Initial cohort aged 60 years

$275.66

0.0126

$27,601

($8,783, $73,948)

Men only (aged 50 years)

$286.23

0.0130

$27,182

($9,200, $70,783)

Women only (aged 50 years)

$334.53

0.0049

$46,408

($17,199, $118,383)

  1. 1. ICER of simple average results - single mean cost and effect differences.
  2. 2. Statistically significantly different mean costs and effects between groups (p < 0.001)
  3. 3. Average ICER of 1,000 simulations, not ICER of average results.